Published: September 27, 2019

Introduction {#sec1}
============

The lifelong production of all human blood cell lineages is ensured by hematopoietic stem cells (HSCs) ([@bib31], [@bib34]). In adults, HSCs′ functions are maintained and tightly regulated in the specialized bone marrow (BM) microenvironment, referred to as the BM niche ([@bib31], [@bib34]). This environment is defined by unique physical properties ([@bib17], [@bib21], [@bib23]) and includes differentiated cells, extracellular matrix, and signaling factors ([@bib41], [@bib53]) essential for cell differentiation, survival ([@bib24]), and self-renewal ([@bib26], [@bib31]). However, the precise cellular and molecular composition of the human hematopoietic niche remains elusive ([@bib7], [@bib52]). Our understanding of human hematopoiesis largely relies on the analogy made with the mouse system ([@bib46]). In reality, despite commonly inherited genetic traits, HSC basic biology differs across species and the corresponding interactions with their niches are not fully conserved ([@bib15], [@bib52]). In consequence, information derived from murine studies does not systematically correlate with the human system, raising concerns about their direct relevance toward therapeutic developments ([@bib15]).

Advanced xenotransplantation models offer robust engraftment and development of human hematopoiesis in mouse bones ([@bib43]). This has significantly contributed to the progressive understanding of human HSC functions in healthy and pathological setups ([@bib4], [@bib40]). However, such humanized mouse models are incompatible with the organizational and functional study of the HSC niche, because the BM microenvironment remains entirely murine.

As an alternative, the possibility to engineer ectopic humanized ossicles (hOss) using human BM-derived mesenchymal stromal cells (hMSCs) is receiving increasing attention ([@bib8], [@bib40], [@bib48]), with demonstration of robust human blood engraftment in both healthy and malignant scenarios ([@bib1], [@bib30], [@bib40]). Although this is attributed to the presence of hMSCs, their contribution in the functional organization of the niche remains to be investigated.

Here, we propose the genetic engineering of hMSCs together with the use of a recently developed deep multicolor imaging confocal analysis ([@bib11]) to achieve a first quantitative assessment of the distribution and role of hMSCs in hOss. We previously reported a developmental approach to bone organ formation, by *in vitro* chondrogenic priming of hMSCs ([@bib8], [@bib48]). Following hypertrophic cartilage (hyC) formation, the generated tissues remodel into hOss upon subcutaneous implantation in humanized mice ([@bib19]) by recapitulating the endochondral ossification process ([@bib25]). We target the further exploitation of this approach to engineer and characterize customized hematopoietic bone organs, here exemplified by the generation of niches overexpressing stromal-derived factor 1 alpha (SDF1α), through compositional and distributional assessment of their human cellular compartments.

The validation of the methodology bears relevance toward deciphering the human hematopoietic and skeletal systems using advanced and modular or tunable models of higher translational relevance.

Results {#sec2}
=======

Primary hMSCs Can Be Genetically Engineered without Altering Their Capacity to Form Hypertrophic Cartilage {#sec2.1}
----------------------------------------------------------------------------------------------------------

Before cartilage formation, hMSCs were transduced ([Figure 1](#fig1){ref-type="fig"}A) using a VENUS (mock control) or VENUS-SDF1α lentivirus ([Figure S1](#mmc1){ref-type="supplementary-material"}). The transduction allowed the generation of homogeneous VENUS and VENUS-SDF1α hMSCs populations (\>93% and 96% using VENUS and VENUS-SDF1α viruses, respectively, [Figure 1](#fig1){ref-type="fig"}B). The VENUS-SDF1α transduction led to a significant SDF1α overexpression (31-fold increase in RNA levels when compared with VENUS hMSCs, [Figure 1](#fig1){ref-type="fig"}C), with transduced and untransduced MSCs displaying unchanged phenotypes ([Figure S2](#mmc1){ref-type="supplementary-material"}).Figure 1Primary hMSCs Can Be Genetically Engineered without Altering Their Capacity to Form Hypertrophic Cartilage(A) Experimental design for generation of hypertrophic cartilage (hyC). SDF1α, stromal-derived factor 1 alpha.(B) Primary hMSCs were successfully transduced with the VENUS and VENUS-SDF1α lentiviruses, as assessed by flow cytometry. n ≥ 4 biological replicates.(C) The VENUS-SDF1α transduction led to a significantly higher expression of SDF1α levels in corresponding cells before hyC formation. ∗∗p \< 0.01, using non-parametric Mann-Whitney t test. n ≥ 5 biological replicates.(D) All hyC display similar protein secretion patterns during *in vitro* culture time, but VENUS-SDF1α hyC releases higher amounts of SDF1α. n ≥ 3 biological replicates. BMP-2, bone morphogenetic protein-2; MMP-13, matrix metalloproteinase-13; VEGF, vascular endothelial growth factor; IL-8, interleukin-8.(E) VENUS and VENUS-SDF1α successfully displayed features of mature hypertrophic cartilage tissue following 5 weeks of *in vitro* culture, as assessed by histological analysis. Safranin O staining reveals the presence of glycosaminoglycans (red), whereas alizarin red reveals the presence of mineralized tissue (red). Scale bars, 500 μm.(F) After 5 weeks of *in vitro* culture, VENUS-SDF1α hyC successfully displayed a typical hypertrophic molecular profile while exhibiting a significant SDF1α increase.∗∗p \< 0.01, using one-way ANOVA. n ≥ 4 biological replicates. Col2, collagen type 2; RunX2, Runt-related transcription factor 2; ALP, alkaline phosphatase; BSP, bone sialoprotein; OSX, osterix. Data are represented as mean ± SEM.

Cells were subsequently seeded on collagen meshes and primed to form hyC. Over the 5-week course of *in vitro* culture, the total number of cells in the hyC remained stable (1.3 × 10^6^ and 1.2 × 10^6^ at weeks 1 and 5 respectively, [Figure S3](#mmc1){ref-type="supplementary-material"}). During this period, the monitoring of proteins in hyC supernatant revealed comparable release profiles of angiogenic (vascular endothelial growth factor), osteoinductive (bone morphogenetic protein-2), bone remodeling (matrix metalloproteinase-13), and inflammatory (interleukin-8) factors, suggesting similar development of the templates by untransduced (primary hyC) or transduced hMSCs (VENUS and VENUS-SDF1α hyC) ([Figure 1](#fig1){ref-type="fig"}D). VENUS-SDF1α hyC secreted significantly higher amounts of SDF1α (4-fold increase at day 3, [Figure 1](#fig1){ref-type="fig"}D), although a progressive decrease was observed over time.

At the end of the *in vitro* culture, histological analysis indicated the successful formation of mature hyC in all groups, characterized by the large presence of glycosaminoglycans (safranin O, [Figure 1](#fig1){ref-type="fig"}E) and a mineralized ring at the periphery of the tissue (alizarin red, [Figure 1](#fig1){ref-type="fig"}E). Differentiation was confirmed by RT-PCR, revealing activation of chondrogenic (Collagen 2, Sox 9, [Figure 1](#fig1){ref-type="fig"}F) and hypertrophic genes (RUNX2, ALP, BSP, OSX, [Figure 1](#fig1){ref-type="fig"}F) in all hyCs. Importantly, VENUS-SDF1α hyCs were shown to maintain a marked SDF1α overexpression ([Figure 1](#fig1){ref-type="fig"}F) when compared with primary and VENUS hyCs.

Hypertrophic Cartilage with a Targeted SDF1α Enrichment Can Be Generated {#sec2.2}
------------------------------------------------------------------------

After demonstrating the similar quality of hyCs and hOss derived from primary or VENUS hMSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}), VENUS hyCs were further used as the control group allowing for the tracing of hMSCs via the VENUS signal.

Multicolor confocal analysis of thick hyC sections was performed to investigate the presence and distribution of cells and SDF1α in the templates. VENUS cells were homogenously distributed within the tissue, largely embedded into a collagen type 2-rich matrix with detectable SDF1α proteins ([Figure 2](#fig2){ref-type="fig"}A). High-resolution imaging revealed presence of the chemokine intracellularly in both VENUS and VENUS-SDF1α cells in their corresponding hyC ([Figure 2](#fig2){ref-type="fig"}B). The SDF1α protein was also found associated with the extracellular matrix (ECM), as shown by colocalization with collagen type 2, in a more abundant fashion in VENUS-SDF1α samples ([Figure 2](#fig2){ref-type="fig"}B). To confirm microscopic observations, hyCs were lysed and assessed for their content in a panel of growth factors, including SDF1α. VENUS and VENUS-SDF1α hyCs displayed comparable protein contents ([Figure 2](#fig2){ref-type="fig"}C) except a 2-fold SDF1α enrichment in the VENUS-SDF1α templates ([Figure 2](#fig2){ref-type="fig"}C). Consistent with previous observations ([@bib12], [@bib39]), the reported decrease in secreted SDF1α over culture time ([Figure 1](#fig1){ref-type="fig"}D) can be explained by SDF1α′s capacity to bind to the ECM, leading to its progressive embedding. We thus report the successful tuning of cartilage tissue′s composition, through a targeted enrichment of SDF1α content.Figure 2Hypertrophic Cartilage with a Targeted SDF1α Enrichment Can Be Generated(A) VENUS and VENUS-SDF1α hyC consist in cartilage pellets (macroscopic view, left) in which hMSCs (VENUS positive) and the SDF1α protein are found abundantly in the collagen-rich matrix, as assessed by immunofluorescence analysis of thick hyC sections. Col2, collagen type 2. Scale bars, 500 μm.(B) SDF1α is more abundant in the ECM of VENUS-SDF1α hyC, as revealed by high-resolution immunofluorescent imaging. Scale bars, 20 μm. Col2, collagen type 2.(C) A significant and specific SDF1α enrichment is obtained in the VENUS-SDF1α hyC, as assessed by protein quantification. n = 3 biological repeats. ∗∗p \< 0.01, using one-way ANOVA test. Data are represented as mean ± SEM.

Molecularly Engineered hyC Can Remodel into Humanized Bone Organs of Distinct Blood Compositions {#sec2.3}
------------------------------------------------------------------------------------------------

*In vitro-*engineered VENUS and VENUS-SDF1α hyCs were subcutaneously implanted in mice ([Figure 3](#fig3){ref-type="fig"}A). After 6 weeks, when hyCs are expected to be remodeled into bone tissue, animals were intravenously transplanted with CD34+ cord-blood-derived hematopoietic cells to reconstitute human hematopoiesis ([Figure 3](#fig3){ref-type="fig"}A). After a total *in vivo* period of 12 weeks, VENUS and VENUS-SDF1α hyCs remodeled into ectopic ossicles exhibiting macroscopic evidence of vascularization ([Figure 3](#fig3){ref-type="fig"}B). Microtomography scans ([Figure 3](#fig3){ref-type="fig"}C) revealed the formation of mature bone tissue with no quality differences between the two hOss types, consisting in a spheroid organ of 18 ± 2.1 mm^3^ ([Figure S5](#mmc1){ref-type="supplementary-material"}). Confocal microscopy allowed to identify human blood cells in the hOss, forming heterogeneous "islets" of human hematopoiesis, indicating successful engraftment ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Molecularly Engineered hyC Can Remodel into Humanized Bone Organs of Distinct Blood Compositions(A) Experimental design for the generation of humanized ossicles (hOss). Engineered hyCs are implanted into immunocompromised animals. Mice are humanized 6 weeks later by intravenous transplantation of human CD34+ isolated from cord blood. Constructs are retrieved 6 weeks later for analysis.(B and C) (B) VENUS and VENUS-SDF1α hyCs successfully remodeled into ossicles, as shown macroscopically by blood colonization and (C) by microtomographic scans revealing the formation of mature bone tissue. Ossicles were retrieved after 12 weeks *in vivo*. Scale bars, 0.5 mm.(D) Humanized ossicles display a chimeric blood composition organized in "islets" of human hematopoieisis.(E) SDF1α-overexpressing ossicles displayed higher frequencies of human blood populations, as assessed by flow cytometry. n ≥ 18 biological replicates from four independent experiments. ∗p \< 0.5, using one-way ANOVA test. CMPs, common myeloid progenitors; HSCs, hematopoietic stem cells; HSPCs, hematopoietic stem and progenitor cells; MEPs, megakaryocyte-erythroid progenitors; MPPs, multipotent progenitors. Data are represented as mean ± SEM.

Human blood populations were quantified by flow cytometry in retrieved hOss and corresponding mouse bones ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Engraftment of human blood cells was similar with an average hCD45 chimerism level of 40% ([Figure 3](#fig3){ref-type="fig"}E). VENUS hOss and mouse bones displayed comparable frequencies of naive and more committed blood populations ([Figures 3](#fig3){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}C), whereas hOss overexpressing SDF1α showed significantly higher frequencies of multipotent progenitors (MPPs) and common myeloid progenitors (CMPs)/megakaryocyte-erythroid progenitor (MEPs) (2.7- and 2.4-fold increase, respectively) and superior HSPC and HSC content (1.8- and 1.9-fold increase, respectively), although not reaching significance.

The functionality of hCD45/CD34+ cells retrieved from mouse bones or hOss was evaluated by *in vitro* colony formation unit (CFU) assays. Cells were capable of efficiently giving rise to all myeloid colonies, but the hCD45/CD34+ fraction derived from hOss displayed a significantly higher potential to form hematopoietic colonies, including GEmM, than the corresponding population retrieved from mouse bones ([Figure S6](#mmc1){ref-type="supplementary-material"}D). No differences in CFU activity were observed between cells retrieved from VENUS or VENUS-SDF1α hOss, suggesting that the SDF1α overexpression did not affect stem and progenitor functionalities. We thus validate the generation of SDF1α-customized hOss, composed of an increased frequency of HSPCs without alterations of their functionality.

Quantitative Microscopy of Bone Organs Reveals the Reconstitution of a Human Mesenchymal Niche including Rare Mesenchymal-Hematopoietic Physical Interactions {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

Deep confocal analysis on both types of hOss offered a quantitative understanding of the reconstituted BM environment. Serial sectioning of hOss allowed gathering comprehensive 3D information ([Figures 4](#fig4){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}A) and indicated an intense vascularization surrounding the hOss with its cavity largely filled by BM cells. The hOss were also connected to the host nervous system as shown by evidences of innervation (peripherin, [Figure S7](#mmc1){ref-type="supplementary-material"}B).Figure 4Quantitative Microscopy of Bone Organs Reveals the Reconstitution of a Human Mesenchymal Niche Including Rare Mesenchymal-Hematopoietic Physical Interactions(A) Multidimensional confocal immunofluorescence imaging allows for the reconstitution of hOss for 3D quantitative information retrieval (left). Top view of a transverse hOss section (right) illustrating the internal bone marrow cavity (DAPI) and intense peripheral vascularization (lamimin). Scale bars, 400 μm.(B) Top: implanted hMSCs (VENUS positive) demonstrate fate plasticity by acquiring multiple niche cell phenotypes. Scale bars, 20 μm. Bottom: fate quantification of VENUS hMSCs based on the segmentation of immunofluorescence data. Stromal cells, venus+/CD90+/stroma localization; osteocytes, venus+/ALP-/localization in bone nodules; osteoblasts, venus+/ALP+/localization at the bone and bone marrow interface; vascular associated, venus+/distance to lamimin+ vessels \< 1 μm; ALP, alkaline phosphatase. n ≥ 3 biological replicates.(C) The SDF1α protein was expressed by blood cells and also found more abundantly in VENUS cells from the VENUS-SDF1α ossicles. Right and b are magnification panels.(D) Deep confocal analysis of hOss allows for the identification and localization of a rare HSPC subset (arrow, hCD45/CD34/CD90), found directly in contact with hMSC-derived niche cells. n = 10 events detected in 5.9 mm^3^ of tissue scanned. Data are represented as mean ± SEM.

The presence of hMSCs in both VENUS and VENUS-SDF1α organs was identified by VENUS expression ([Figure S8](#mmc1){ref-type="supplementary-material"}A). The segmentation of VENUS cells ([Figure S8](#mmc1){ref-type="supplementary-material"}A) in corresponding sections ([Figure S8](#mmc1){ref-type="supplementary-material"}B) allowed determining the average number of hMSCs per hOss. From the 1.2 × 10^6^ hMSCs present in the hyC at the time of implantation, only 0.1 × 10^6^ were still populating the hOss, corresponding to a 90% decrease ([Figure S8](#mmc1){ref-type="supplementary-material"}C). To corroborate this finding, flow cytometry quantification of VENUS cells after hOss digestion was also performed, giving a number of hMSCs per hOss of 0.06 × 10^6^ ([Figure S8](#mmc1){ref-type="supplementary-material"}C). The difference is likely due to difficulty to retrieve bone-embedded hMSCs and adipocytes. The observed hMSC death was not due to the animal irradiation, because non-irradiated hOss gave similar numbers (0.07 × 10^6^, [Figure S8](#mmc1){ref-type="supplementary-material"}C).

Remarkably, in the engineered hOss, hMSCs were associated with an important fate diversity following the remodeling of hyC. HMSCs′ fates in bone organs were quantified by specific segmentation strategies (c.f. [Methods](#sec4){ref-type="sec"} section and [Figures S8](#mmc1){ref-type="supplementary-material"} and [S9](#mmc1){ref-type="supplementary-material"}). First, no significant differences could be observed between VENUS and VENUS-SDF1α hOss, indicating that the hMSCs′ genetic modification did not impact their subsequent fate decisions upon hOss formation. The capacity to manipulate hMSCs without impairing their endochondral program allows the stringent assessment of SDF1α effects. As such, the previously observed distinct human blood composition in VENUS-SDF1α hOss can be strictly attributed to the factor overexpression.

In all hOss, hMSCs were abundantly found within the BM stroma (stromal, 45% and 47% in VENUS and VENUS-SDF1α hOss respectively, [Figure 4](#fig4){ref-type="fig"}B), exhibiting a fibroblast-like shape and positivity for CD90 ([Figure S9](#mmc1){ref-type="supplementary-material"}A). A large fraction of them (47% and 50%, respectively; [Figure 4](#fig4){ref-type="fig"}B) was directly associated with vasculature (0--1 μm distance to vessels). The hMSCs′ enrichment at vessel sites was confirmed by comparison to a random dots distribution ([Figure S9](#mmc1){ref-type="supplementary-material"}C). HMSCs also differentiated into the osteogenic lineage in the form of osteocytes embedded in the bone matrix (osteocytes, [Figures 4](#fig4){ref-type="fig"}B and [S9](#mmc1){ref-type="supplementary-material"}A), accounting for 36% (VENUS hOss) and 41% (VENUS-SDF1α hOss) of total VENUS cells. Lining osteoblasts were less abundant (19% in VENUS hOss versus 12% in VENUS-SDF1α hOss, [Figures 4](#fig4){ref-type="fig"}B and [S9](#mmc1){ref-type="supplementary-material"}A). To a lower extent, we also identified hMSCs differentiated into the adipogenic lineage, as shown by the presence of VENUS-positive adipocytes ([Figure S7](#mmc1){ref-type="supplementary-material"}D).

To obtain a better understanding of the observed *in vivo* fate diversity, we further investigated the proportion of hMSCs committed to certain lineages before implantation, at the hyC stage (5 weeks *in vitro* culture). The Sox-9 and RUNX2 transcription factors are typically associated with chondrogenic ([@bib3]) and osteoblastic ([@bib16]) differentiation, respectively; 41.3% (±5.6) of the cells were positive for Sry-box 9 (Sox-9), 6.3% (±5) expressed the Runt-related transcription factor 2 (RUNX2), and 10.8% (±5.6) were both RUNX2 and Sox-9 positive ([Figure S10](#mmc1){ref-type="supplementary-material"}). No cells showed positivity for the adipocytic marker peroxisome proliferator-activated receptor gamma ([@bib28]). As such, the majority of our cells were chondrocytes (Sox-9 positivity), hypertrophic chondrocytes (Sox-9 and/or RUNX2 positivity), or osteoblasts (RUNX2 positivity). Interestingly, despite the 5-week course of differentiation, 29.9% ± 1.6% maintained the expression of Stro-1, a progenitor marker associated with multipotency ([@bib29]). This indicates that some hMSCs are not fully committed at the end of the *in vitro* differentiation stage and acquire their definitive function after implantation.

Further immunofluorescence analysis of the ossicles was performed. SDF1α staining revealed the presence of the protein in the marrow ([Figure 4](#fig4){ref-type="fig"}C), expressed by blood cells ([@bib13]). The SDF1α protein could also be detected in hMSCs-derived cells from VENUS-SDF1α hOss ([Figure 4](#fig4){ref-type="fig"}C). Acquisition of deep multicolor staining was further performed for the identification of hMSC-derived niche cells (positive for VENUS) and particular HSPC populations within engineered hOss. This allowed the localization of a very rare subset of HSPCs (hCD45+/CD34+/CD90+) described to be enriched for functional HSCs, which was consistently in physical contact (less than 1 μm distance) with VENUS cells, in both VENUS and VENUS-SDF1α niches (n = 10 events detected in 5.9 mm^3^ of tissue scanned, [Figure 4](#fig4){ref-type="fig"}D). To ensure that those interactions did not result from a random distribution, we investigated the probability for HSPCs touching an hMSC ([Figure S11](#mmc1){ref-type="supplementary-material"}). This probability was found to be 36% (±11), although 100% of the HSPCs we found were in contact with hMSCs.

This recurrent physical interaction between the human stromal and naive hematopoietic compartments, combined with the finding that SDF1α customization leads to changes in frequencies of hematopoietic populations, supports a functional contact-triggered regulation of HSPCs by the human mesenchymal compartment, to date only reported in mouse studies ([@bib20], [@bib44]).

Discussion {#sec3}
==========

We report the engineering and characterization of customized human hematopoietic bone organs. The method relies on the genetic modification of primary hMSCs, their priming to recapitulate the developmental program of endochondral ossification ([@bib25]), and quantitative multidimensional imaging of the reconstituted human BM environment.

The study of hematopoiesis in a humanized context is a primary challenge. The generation of transgenic animals supporting human engraftment is associated with some limitations ([@bib14]), including time-consuming single-gene targeting, the unpredictable biological outcome (e.g., embryonic lethality, low efficiency, absence of recognizable phenotypes), and the often non-tissue-specific nature if at all conditional. Instead, our strategy relies on the exploitation and characterization of the hOss model, using hMSCs as cellular vectors for the targeted delivery of factors influencing the composition of the human blood compartment. The introduced modification is thus confined within the BM tissue as ensured by hMSC-derived niche cells.

The biological validation of the method was performed using SDF1α as a known factor influencing stem cell behavior. SDF1α has been reported both as stem cell chemoattractant ([@bib2], [@bib27], [@bib33]) and pro-quiescent molecule ([@bib22], [@bib51]), thus offering multiple readouts to validate the effects of its overexpression in hOss. Pre-existing molecular engineering approach ([@bib9], [@bib10]) models did not investigate the effect of the genetic modification on the reconstituted human niche environment. As a direct consequence, impact on the blood compartment could not be strictly attributed to the factor′s secretion. Here, the SDF1α overexpression was shown to specifically affect the human blood composition while not affecting the fate and distribution of implanted hMSCs. The capacity to manipulate hMSCs without impairing their endochondral program is a pre-requisite for the direct assessment of SDF1α effects. We observed a specific enrichment in CMPs/MEPs, MPPs, and HSC populations in SDF1α-overexpressing hOss. All these populations express the CXCR4 receptor ([@bib50]), thus being sensitive to the SDF1α chemoattractant effect ([@bib38]). The previously reported SDF1α-driven mobilization of CD34+ cells by stromal cells included the recruitment of more committed erythroid, lymphoid, and myeloid lineages ([@bib6]). Our observations are thus in line with the existing literature, although our study is the first exploiting a humanized approach to evidence an SDF1α-triggered effect. Although our model was previously validated for the engraftment of fully functional HSCs ([@bib19]), secondary transplantation would be required to assess putative SDF1α effects on the self-renewal of long-term repopulating stem cells.

Interestingly, the association of SDF1α with proteoglycans---the main constituents of cartilaginous ECM ([@bib45])---was reported to strongly promote the migration of HSPCs ([@bib35]). This might suggest that the observed effects result from preferential homing at the time of engraftment ([@bib27]), although a different cycling rate of HSPCs cannot be excluded.

In our study, we used advanced microscopy tools to monitor hMSCs within the engineered tissues, from the *in vitro* hyC stage to the fully remodeled hOss. As easily accessible organs tunable in size, quantitative 3D information on the hOss cellular composition could be retrieved and offered a comprehensive understanding of the human niche in this *in vivo* setting. This revealed a remarkable degree of hMSCs′ plasticity in the model, giving rise to several niche phenotypes, including lining osteoblasts, osteocytes, stromal cells, and adipocytes. Distance analyses indicated not only a strong association of hMSCs with vasculature but also direct physical interactions with HSPCs. The observed fate diversity may derive from a pool of hMSCs with no signs of chondrogenic or osteoblastic commitment at the hyC stage. However, lineage-committed hMSCs have also been described as capable of transdifferentiation ([@bib49]).

Although previous studies reported the presence of hMSCs in ossicles ([@bib1], [@bib30], [@bib40]), their functional status has not been rigorously demonstrated beyond their support for human blood engraftment. Our work evidences for the first time a functional regulatory role of hMSCs in the model, validated by the SDF1α customization leading to distinct changes in frequencies of hematopoietic populations. These were achieved despite the relatively low number of hMSCs composing the niche and supporting human blood cell engraftment. Collectively, these findings reinforce the notion that hMSCs are essential niche players ([@bib31], [@bib34]) in the engineered ossicles and support a contact-triggered regulation of HSPCs by the mesenchymal compartment, only previously reported in mouse studies ([@bib44]). The detection of a high number of interactions of a more specific HSC phenotype (CD45+/CD34+/CD38-/CD45RA-/CD90+/CD49f+) ([@bib18]), which requires challenging immunofluorescence multiplexing, would, however, be required to provide direct evidence of a physical interaction between hMSCs and functional HSCs.

The functional role of hMSCs in the hOss model supports their use for the molecular engineering of human niches. The importance of the proximity between hMSCs and HSPCs could be further evaluated by overexpression of signaling molecules requiring direct contact of adjacent cells for influencing their fate decisions, e.g., Notch ligands ([@bib5]). The paradigm of customization can also be further explored with additional factors putatively affecting stem cell homing/localization/function in pathological scenarios (e.g., by engraftment of leukemic primary material) and include the impact assessment on the human niche compartment. In fact, the hOss could be valuable for the identification of specific human niche cell populations, derived from the implanted hMSCs. This is of particular importance in pathologic scenarios, in which the role of the stroma and associated factors in disease evolution remains elusive ([@bib46], [@bib47]). Our model could thus help deciphering the complex phenotypes and functions associated with hMSCs ([@bib32], [@bib36]) in myeloid or lymphoid malignancies. Along the same line, our model could also be exploited to study the engraftment of metastatic solid tumors (e.g., breast, prostate) that naturally migrate to bones, including those for which SDF1α has been shown to be highly expressed in BM sites of tumor metastasis ([@bib42]).

Toward these objectives, the exploitation of dedicated cell lines may not only facilitate molecular engineering of hMSCs but also potentially lead to their higher survival in the BM. This would maximize the therapeutic delivery of factors impacting engrafted healthy or malignant blood populations. However, so far no hMSC line was proved capable of recapitulating the endochondral process.

Finally, using similar knockout or knockin strategies in hMSCs, we also envision the possibility of identifying key molecular players of the endochondral program, by studying their impact on hMSC fate decision. The ossicle would thus be exploited as a developmental model of human bone formation.

Limitations of the Study {#sec3.1}
------------------------

For immunofluorescence analysis, the hCD45+/CD34+/CD90 + phenotype was used to identify HSPCs. Of this population, 24.6% are CD34+/CD38-/CD45RA-CD90+, of which 5% were reported to be functional HSCs in freshly isolated cord blood ([@bib37]). The hCD45+/CD34+/CD90 + population thus contains ca. 1.2% functional HSCs. Detection of functional HSCs will require improved HSC markers. In addition, owing to the large required effort, only a small number of these cells were imaged in ossicles. A higher number will allow robust statistical analysis of human MSC-HSPC interactions.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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